Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-4.62%
$13.51
0% positive prob.
5-Day Prediction
-8.13%
$13.01
0% positive prob.
20-Day Prediction
-13.22%
$12.29
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | SELL | -4.62% | -8.13% | -13.22% | 99.8% | Pending |
| Q1 2026 | BUY | +2.00% | +8.82% | +247.12% | 100.0% | +4.27% |
| Q4 2025 | SELL | -4.63% | -8.14% | -13.23% | 100.0% | +3.49% |
SEC 8-K filings with transcript text
Jul 29, 2026 · 100% conf.
1D
-4.62%
$13.51
Act: +0.49%
5D
-8.13%
$13.01
20D
-13.22%
$12.29
2 amrn-ex99_1.htm
Exhibit 99.1
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow
For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation
DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the one-year anniversary of its fully partnered international commercial strategy.
In June 2025, Amarin entered into an exclusive long-term license and supply agreement with Recordati S.p.A. (“Recordati”) to commercialize VASCEPA®/VAZKEPA® (icosapent ethyl or IPE) across 59 countries focused in Europe. This transformational agreement enabled Amarin to significantly reduce its operating expenses while simultaneously expanding VAZKEPA’s presence in one of the world's largest cardiovascular pharmaceutical markets, where cardiovascular disease affects an estimated 62 million people and carries an annual economic burden of approximately €282 billion across the European Union.i While commercialization remains in the early stages, Recordati has made progress advancing pricing, reimbursement, market access and adoption across the licensed territory.
“The strategic actions we have taken are driving stronger results and a path to sustained growth and profitability,” said Aaron Berg, President and Chief Executive Officer. “Amarin’s results for Q2 2026 demonstrated a positive early international sales trajectory as in-market demand increased 59% year over year across our global partner network. Operating expenses, excluding restructuring charges, declined by $16.6 million, or 38% compared to Q2 2025, in line with the previously announced $70 million annual cost savings initiative that we have now completed. We also maintained our leading U.S. IPE sales presence for VASCEPA. We are confident in the significant opportunities that lie ahead to improve patient outcomes, and continue to work closely with Barclays, our exclusive financial advisor, to explore additional potential pathways to further enhance shareholder value."
Select Operational Highlights and Outlook
• Across our global partner network, in-market demand for VASCEPA/VAZKEPA rose by 59% in Q2 2026 compared to Q2 2025, including 90% year-to-date growth in in-market volume in China versus the same period last year.
• In-market demand in Europe for VAZKEPA rose by 69% in Q2 2026 from Q2 2025.
• As of June 30, 2026, VASCEPA / VAZKEPA was commercially available in 22 countries across the globe.
• As of June 30, 2026, VAZKEPA is commercialized in 11 countries in Europe, with pricing, reimbursement, market access and adoption continuing to build across additional countries within Recordati’s licensed territory.
• The Company continues to work closely with our partners to advance regulatory submissions and support partners' needs through various stages of review and market launch preparations. Momentum remains strong
across Europe and Asia, with Singapore and South Korea progressing toward anticipated near-term commercialization.
• The Company’s share of the U.S. IPE market increased to 48% in Q2 2026 compared to 43% in Q2 2025. VASCEPA branded prescriptions rose by 14% from Q2 2025.
• The Company expects that U.S. volumes will remain consistent throughout FY 2026.
Select Financial Highlights and Outlook
• Operating expenses declined by $39.3 million, or 59% compared to Q2 2025, in line with the previously announced and now completed $70 million annual cost savings initiative. Excluding restructuring charges incurred in Q2 2025, operating expenses declined by $16.6 million, or 38%, in line with the previously announced and now completed $70 million annual cost savings initiative.
• Inventories as of June 30, 2026 declined by $19.5 million from March 31, 2026 and by $31.8 million from December 31, 2025.
• Cash as of June 30, 2026 was $314.6 million, compared to $302.6 million at December 31, 2025. The Company expects cash to grow by approximately 10% as of December 31, 2026 compared to December 31, 2025.
• The Company remained debt free as of June 30, 2026.
Financial Highlights
($ in millions)
% Change
% Change
Total Net Revenue
$42.2
$72.7
(42)%
$87.3
$114.8
(24)%
Operating Expenses
$27.0
$66.3
(59)%
$56.1
$108.2
(48)%
Operating Loss
$(12.0)
$(16.0)
25%
$(23.3)
$(32.7)
29%
Operating Margin %*
(28)%
(22)%
(6) pts
(27)%
(29)%
2 pts
Net Loss
$(7.7)
$(14.1)
46%
$(18
Apr 29, 2026 · 100% conf.
1D
+2.00%
$14.58
Act: -2.52%
5D
+8.82%
$15.55
Act: +4.27%
20D
+247.12%
$49.60
Act: +0.84%
2 amrn-ex99_1.htm
Exhibit 99.1
Amarin Reports 2026 First Quarter Financial Results
Total Revenue Increased Led by Higher International Sales
Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow
Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).
“Our results for Q1 2026 reflected the early yet measurable progress generated by our refined global business model which we adopted in mid-2025,” said Aaron Berg, President and Chief Executive Officer.
“The promise of our fully-partnered international commercial strategy – anchored by our European-focused exclusive licensing and supply agreement with Recordati S.p.A. (Recordati) - was reflected in higher European product revenue in Q1 2026 compared to Q4 2025. This consecutive quarterly growth was attributable to strong in-market demand for VAZKEPA® (icosapent ethyl) and the priority assigned by Recordati to expand the commercial reach for this proven therapy. While acknowledging that European sales will vary quarter to quarter, especially in the early days of this new partnership, these initial results are encouraging. Recordati has commenced commercial efforts of VAZKEPA in 10 countries, including a Q4 2025 launch in Italy, and plans to expand its distribution across Europe over the next several years. We are also seeing good growth from our active commercial partners outside of Europe.
“Our U.S. franchise continues to demonstrate remarkable resilience, where we have maintained our leading market share for VASCEPA® more than five years since the introduction of generics. Industry prescription data for Q1 2026 showed an overall increase in the icosapent ethyl (IPE) market while VASCEPA-branded prescriptions rose by 17% compared to Q1 2025. We expect that volumes will remain stable throughout 2026. Our streamlined U.S. operation remains an efficient, cash generating engine for our Company.”
He continued, “We are encouraged by the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update from March of this year that supports the broader clinical role of IPE in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides. These guidelines shift CV care toward early, lifelong prevention and a more comprehensive risk approach beyond just lowering LDL cholesterol. In recognizing that high triglyceride levels contribute to CV events in many patients, this framework underscores the need for additional therapies beyond statins to address this care gap. This evolutionary perspective on CV risk management is timely and strengthens our position to address the burden of CV disease in patients and across the healthcare ecosystem.”
Mr. Berg concluded, “We have created a new version of Amarin – focused, leaner, and both financially and operationally stronger than at any time in our recent history. The growth initiatives we have undertaken and building industry tailwinds increasingly focused on the needs of patients with elevated triglycerides have positioned us well
for 2026. Our team is executing with focus and discipline to achieve our objectives and deliver shareholder value, while continuing to work closely with Barclay’s, our exclusive financial advisor, in exploring additional potential pathways to further enhance shareholder value. While there is still work to be done, we look forward to our future with confidence.”
Q1 2026 Financial Highlights
($ in millions)
% Change
Total Net Revenue
$45.1
$42.0
7%
Operating Expenses
$29.1
$41.9
(31)%
Operating Loss
$(11.3)
$(16.8)
(32)%
Operating Margin %*
(25)%
(40)%
NM
Net Loss
$(10.5)
$(15.7)
33%
Net Margin
(23)%
(37)%
NM
Cash
$307.8
$281.8
*Operating margin is calculated as operating loss divided by total net revenue
NM – Not Meaningful
Peter Fishman, Amarin’s Chief Financial Officer, said, “We are encouraged by our Q1 2026 performance under our new business model. We achieved higher total revenue, led by growth from our partners, and a continued decline in our operating expenses, both of which led to significantly narrowed losses compared to the same period last year. We remain on track to realize the approximately $70 million in cost savings and have incurred nearly all of the associated restructuring costs. Finally, we generated positive cash flow for the second consecutive quarter and continue to expect to be cash flow positive for full year 2026.”
Q1 2026 Financial Performance
Comparisons to Q1 2025, unless otherwise sta
Feb 25, 2026 · 100% conf.
1D
-4.63%
$13.40
Act: +0.50%
5D
-8.14%
$12.91
Act: +3.49%
20D
-13.23%
$12.19
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482026-02-252026-02-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 25, 2026 Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
8th Floor, One Central Plaza, Dame Street, Dublin 2, Co. Dublin, D02 K7K5, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 25, 2026, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025 and 2024 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated February 25, 2026 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 25, 2026
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
Jan 8, 2026 · 100% conf.
1D
-4.63%
$13.40
Act: +0.50%
5D
-8.14%
$12.91
Act: +3.49%
20D
-13.23%
$12.19
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482026-01-082026-01-08
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2026 Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
8th Floor, One Central Plaza, Dame Street, Dublin 2, Co. Dublin, D02 K7K5, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: + 353 1 6699 020 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On January 8, 2026, Amarin Corporation plc (the “Company”) issued a press release announcing its preliminary unaudited 2025 financial highlights, providing a summary of key 2025 operational accomplishments, and outlined 2026 priorities (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under Item 2.02 and in the Press Release furnished as Exhibit 99.1 herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated January 8, 2026 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2026
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
Oct 29, 2025
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482025-10-292025-10-29
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 29, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
8th Floor, One Central Plaza, Dame Street, Dublin 2, Co. Dublin, D02 K7K5, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 29, 2025, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025 and 2024 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated October 29, 2025 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 29, 2025
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
Jul 30, 2025
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482025-07-302025-07-30
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
8th Floor, One Central Plaza, Dame Street, Dublin 2, Co. Dublin, D02 K7K5, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On July 30, 2025, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and six months ended June 30, 2025 and 2024 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated July 30, 2025 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 30, 2025
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
May 7, 2025
8-K
0000897448falseAMARIN CORP PLC\UK00-000000000008974482025-05-072025-05-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
8th Floor, One Central Plaza, Dame Street, Dublin 2, Co. Dublin, D02 K7K5, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On May 7, 2025, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three months ended March 31, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated May 7, 2025 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 7, 2025
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
Mar 12, 2025
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482025-03-122025-03-12
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 12, 2025
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, One Central Plaza, 5th Floor, 36 Dame Street, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 12, 2025, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2024 and 2023 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 3.03 Material Modification to Rights of Security Holders.
On March 12, 2025, Amarin announced its intent to effect an adjustment in the ratio of its American depositary shares (“ADSs”) to its ordinary shares, £0.50 par value per share (“Ordinary Shares”) from one (1) ADS representing one (1) Ordinary Share to one (1) ADS representing twenty (20) Ordinary Shares (the “ADS Ratio Change”). The ADS Ratio Change will result in a one for twenty reverse split of issued and outstanding ADSs, and it will have no effect on the Ordinary Shares. The ADS Ratio Change is expected to become effective on or about April 11, 2025 (the “Effective Date”).
As a result of the ADS Ratio Change, the trading price of Amarin's ADSs is expected to increase proportionally, but Amarin can give no assurance that the trading price per ADS after the ADS Ratio Change will be equal to or greater than twenty (20) times the trading price per ADS before the change.
Item 7.01 Regulation FD
On March 12, 2025, Amarin issued a press release announcing the ADS Ratio Change. A copy of this press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 7.01 and the attached Exhibit 99.1 are being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing of Amarin under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated March 12, 2025 (furnished herewith)
99.1
Press Release, dated March 12, 2025 (furnished herewith)
104
Cover Page Interactive Data File (emb
Oct 30, 2024
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482024-10-302024-10-30
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 30, 2024
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, One Central Plaza, 5th Floor, 36 Dame Street, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 30, 2024, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and nine months ended September 30, 2024 and 2023 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated October 30, 2024 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 30, 2024
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
Jul 31, 2024
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482024-07-312024-07-31
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 31, 2024
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 31, 2024, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and six months ended June 30, 2024 and 2023 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated July 31, 2024 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 31, 2024
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
President and Chief Executive Officer
May 1, 2024
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482024-05-012024-05-01
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 1, 2024
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 1, 2024, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three months ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated May 1, 2024 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 1, 2024
Amarin Corporation plc
By:
/s/ Patrick Holt
Patrick Holt
President and Chief Executive Officer
Feb 29, 2024
8-K
0000897448falseAMARIN CORP PLC\UK00-000000000008974482024-02-292024-02-29
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 29, 2024
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 29, 2024, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023 and 2022 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated February 29, 2024 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 29, 2024
Amarin Corporation plc
By:
/s/ Patrick Holt
Patrick Holt
President and Chief Executive Officer
Jan 10, 2024
8-K
False0000897448AMARIN CORP PLC\UK00-000000000008974482024-01-102024-01-10
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 10, 2024
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 10, 2024, Amarin Corporation plc (the “Company”) issued a press release announcing its preliminary 2023 revenue results and year end cash position, and 2024 priorities (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1.
Item 7.01. Regulation FD Disclosure.
The Company will present further details on the matters noted above at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 4:30 p.m. Eastern Time/1:30 Pacific Time, which presentation will be accessible by a live webcast through the Company’s website at https://investor.amarincorp.com/events-and-presentations/events. A copy of the Company’s investor deck, which will be referenced during the Company’s webcast presentation, is furnished herewith as Exhibit 99.2
The information set forth under Item 2.02, Item 7.01, and in the Press Release and the Investor Deck furnished as Exhibit 99.1 and Exhibit 99.2 herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated January 10, 2024 (furnished herewith)
99.2
Investor Deck, dated January 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 10, 2024
Amarin Corporation plc
By:
/s/ Patrick Holt
Patrick Holt
President and Chief Executive Officer
Nov 1, 2023
8-K
false0000897448AMARIN CORP PLC\UK00-000000000008974482023-11-012023-11-01
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 1, 2023
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 1, 2023, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 and 2022 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated November 1, 2023 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 1, 2023
Amarin Corporation plc
By:
/s/ Patrick Holt
Patrick Holt
President and Chief Executive Officer
Aug 2, 2023
8-K
0000897448falseAMARIN CORP PLC\UK00-000000000008974482023-08-022023-08-02
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 2, 2023
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 2, 2023, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and six months ended June 30, 2023 and 2022 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated August 2, 2023 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 2, 2023
Amarin Corporation plc
By:
/s/ Patrick Holt
Patrick Holt
President and Chief Executive Officer
Jul 18, 2023
8-K
AMARIN CORP PLC\UK 00-0000000 0000897448 false 0000897448 2023-07-18 2023-07-18
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 18, 2023
Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 - 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +353 1 6699 020 Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On July 18, 2023, Amarin Corporation plc (“Amarin” or the “Company”) issued a press release announcing its preliminary financial results for the three months ended June 30, 2023 (the “Press Release”). These financial results are based on preliminary information and management estimates for the three months ended June 30, 2023, are not a comprehensive statement of Amarin’s financial results, and are subject to completion of Amarin’s financial closing procedures. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 2.05 Costs Associated with Exit or Disposal Activities.
On July 18, 2023, as described in the Press Release, Amarin announced that it was implementing a new organizational restructuring program (the “ORP”), resulting in the elimination and consolidation of certain roles across the organization, both in the United States and abroad, representing a reduction of the total Amarin employee base by approximately 30% from current levels. Management, with oversight and guidance of the Amarin board of directors (the “Board”), determined to implement the ORP following a review of Amarin’s business and to better position the organization for a new strategic focus. The Company expects these actions will reduce operating costs by approximately $40 million annually. As part of the ORP, the Board promoted several members of the Company’s management team, including Tom Reilly, the Company’s Senior Vice President, Chief Financial Officer and Secretary (and principal financial and accounting officer), who was promoted to Executive Vice President, Chief Financial Officer & Head of Global HR (and principal financial and accounting officer), with an increased base salary amount of $560,000. Amarin estimates that it will incur approximately $10 million in charges related to the ORP, substantially all of which are cash expenditures for one-time termination benefits and associated costs. Amarin expects to record the charges in the second quarter of 2023 and to make substantially all of the related payments by December 31, 2023.
Item 5.02. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
May 3, 2023
8-K
00-0000000AMARIN CORP PLC\UK0000897448false00008974482023-05-032023-05-03
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 3, 2023
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 3, 2023, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three months ended March 31, 2023 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated May 3, 2023 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 3, 2023
Amarin Corporation plc
By:
/s/ Aaron Berg
Aaron Berg
Interim President and Chief Executive Officer
Mar 1, 2023
8-K
00-0000000AMARIN CORP PLC\UK0000897448false00008974482023-03-012023-03-01
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 1, 2023
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 1, 2023, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022 and 2021 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated March 1, 2023 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 1, 2023
Amarin Corporation plc
By:
/s/ Karim Mikhail
Karim Mikhail
President and Chief Executive Officer
Jan 10, 2023
8-K
AMARIN CORP PLC\UK 00-0000000 false 0000897448 0000897448 2023-01-10 2023-01-10
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023
Amarin Corporation plc (Exact name of registrant as specified in its charter)
England and Wales
000-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court 112-114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: +353 (0) 1 6699 020 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 10, 2023, Amarin Corporation plc (the “Company”) issued a press release announcing its preliminary 2022 revenue results and year end cash position, and 2023 priorities (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure
The Company will present further details on the matters noted above at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 8:15 p.m. Eastern Time/5:15 Pacific Time, which presentation will be accessible by a live webcast through the Company’s website at https://investor.amarincorp.com/events-and-presentations/events. A copy of the Company’s investor deck, which will be referenced during the Company’s webcast presentation, is furnished herewith as Exhibit 99.2 The information set forth under Item 2.02, Item 7.01, and in the Press Release and the Investor Deck furnished as Exhibit 99.1 and Exhibit 99.2 herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated January 10, 2023 (furnished herewith)
99.2
Investor Deck dated January 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 10, 2023
Amarin Corporation plc
By:
/s/ Karim Mikhail
Karim Mikhail
President and Chief Executive Officer
Oct 27, 2022
8-K
0000897448AMARIN CORP PLC\UKfalse00-000000000008974482022-10-272022-10-27
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 27, 2022
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
England and Wales
0-21392
Not applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112 – 114 St Stephens Green, Dublin 2, Ireland
Not applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: +353 1 6699 020
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 27, 2022, Amarin Corporation plc (“Amarin”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022 and 2021 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release (results of operations), dated October 27, 2022 (furnished herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 27, 2022
Amarin Corporation plc
By:
/s/ Karim Mikhail
Karim Mikhail
President and Chief Executive Officer
This page provides Amarin Corporation plc (AMRN) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on AMRN's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.